Abstract
Introduction
For decades, the effi cacy of hormone replacement therapy (HRT) for some of
menopause' s most troublesome symptoms eliminated any incentive to develop new
approaches to treatment. However, data questioning the safety of
estrogen-containing therapies have galvanized researchers and drug developers
to begin investigating new mechanisms to treat menopausal symptoms that can
capitalize on the newly realized need for safer treatment options, although
these agents will still be challenged by the effi cacy of HRTs.
Questions Answered in This Report
- Menopause is a natural process of aging that is accompanied by substantial
hormonal changes. What are the symptoms of menopause? What are the causes of
these symptoms? What are the current treatment options? What are the benefi ts
and drawbacks of these treatments?
- Data from the Women' s Health Initiative suggest that estrogen therapy is
not suitable for all women. What are the risks associated with hormone
therapy? Do emerging agents offer safer or more effi cacious treatment
approaches?
- With the fi nal wave of baby boomers reaching menopausal age, the
menopause treatment patient population is on the rise. What were the sales of
menopausal symptom treatments in 2008? How well will emerging agents address
the remaining needs in this market? How will emerging agents fi t into the
treatment algorithm in the future?
Scope
- Overview of menopause: Physiology and symptoms.
- Current treatments: Hormone replacement therapy, selective estrogen
receptor modulators, SSRIs/SNRIs, gabapentin.
- Emerging treatments: Wyeth' s Pristiq, Wyeth' s bazedoxifene/conjugated
estrogens, Depomed' s controlled-release gabapentin, Schering-Plough' s
esmirtazapine.
- Outlook: 2008 market, challenges and opportunities, the potential of
emerging agents, the future of HRT.
- Women' s Health Series: This report is part of Spectrum' s Women' s Health
Series, which focuses on areas of unmet need and the best marketing strategies
to ensure adoption of a new agent into the market for women' s reproductive
health - a sector that exceeded $23 billion in 2007.
Mentioned in This Report
Companies
- Bayer-Schering
- Bionovo
- Boehringer Ingelheim
- Chugai
- Concert Pharmaceuticals
- Depomed
- Eli Lilly
- Forest
- GlaxoSmithKline
- Novartis
- Novo Nordisk
- Pfi zer
- Radius
- Schering-Plough
- Solvay
- Wyeth
| 
View Cart
